

Appl. No. 10/027,400  
Amdt. dated February 17, 2006  
Amendment under 37 CFR 1.116 Expedited Procedure  
Examining Group 1646

PATENT

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

**Claims 1-55 (canceled).**

**Claim 56 (Previously presented):** A method of selecting a molecule capable of inhibiting binding of a PI3 kinase protein which binds to a PDGF receptor polypeptide, the method comprising the steps of:

contacting the PI3 kinase protein with the PDGF receptor polypeptide in the presence of a test molecule in a first step;

contacting the PI3 kinase protein with the PDGF receptor polypeptide in the absence of the test molecule in a second step;

wherein the PDGF receptor polypeptide is selected from the group consisting of

- i) a polypeptide consisting of amino acids beginning at 695 and ending at 798 of a B type hPDGF-R, as shown in SEQ ID NO: 4,
- ii) a polypeptide consisting of amino acids beginning at 604 and ending at 951 of a B type hPDGF-R, as shown in SEQ ID NO: 4,
- iii) a polypeptide consisting of amino acids beginning at 695 and ending at 951 of a B type hPDGF-R, as shown in SEQ ID NO: 4, and
- iv) a polypeptide consisting of amino acids beginning at 557 and ending at 951 of a B type hPDGF-R, as shown in SEQ ID NO: 4;

wherein the polypeptide is phosphorylated at Tyr 751 or at Tyr 740; and

comparing the amount of PDGF receptor binding to PI3 kinase in the first and second steps, wherein a lower level of binding detected in the first step is an indication that the test molecule is capable of inhibiting binding of PI3 kinase to PDGF receptor polypeptide, thereby selecting a molecule capable of inhibiting binding of a PI3 kinase protein to a PDGF receptor polypeptide.

Appl. No. 10/027,400  
Amdt. dated February 17, 2006  
Amendment under 37 CFR 1.116 Expedited Procedure  
Examining Group 1646

PATENT

**Claim 57** (Currently amended): The method of claim ~~57~~ 56, wherein the test molecule is selected from the group consisting of peptides, peptide analogues, organic analogue molecules and drugs.

**Claim 58** (Previously presented): The method of claim ~~57~~ 56, wherein the amount of PDGF receptor binding to PI3 kinase is detected using a protein kinase activity assay.

**Claim 59** (Previously presented): The method of claim ~~57~~ 56, wherein the ~~peptide~~ polypeptide is phosphorylated at Tyr 740.

**Claim 60** (Previously presented): The method of claim ~~57~~ 56, wherein the ~~peptide~~ polypeptide is phosphorylated at Tyr 751.

**Claim 61** (Previously presented): The method of claim ~~57~~ 56, wherein the ~~peptide~~ polypeptide is phosphorylated at Tyr 751 and at Tyr 740.

BEST AVAILABLE COPY